|Other Key Employees and Consultants
Mr. Mickunas joined the Company in December 1999 as Senior Director Clinical & Regulatory Affairs. Mr. Mickunas has over 19 years experience in all aspects of managing clinical trials and regulatory matters for a wide variety of medical devices and procedures as well as pharmaceuticals. Prior to joining the Company Mr. Mickunas served as Director of Regulatory Affairs at LeukoSite, Inc. (previously CytoMed, Inc.) from 1998 to December 1999; Director of Regulatory Affairs at Del Laboratories from 1996-1998; Clinical and Regulatory Affairs Consultant at Clinnovation, Inc from 1989 to 1996; Manager of Clinical Trials for Parexel International from 1987 to 1989; and various other clinical and regulatory positions prior to 1987 at Analytical Biosystems Corp., Sandoz Research Institute, and Vicks Research Center. In all of his most recent positions, Mr. Mickunas was the primary liaison with the FDA for the companies he served. He has managed several successful FDA submissions related to biologics and medical devices. He has a B.S. in Biology from Fairleigh Dickinson University and a M.A. in Corporate and Political Communications from Fairfield University. Additionally, he has completed extensive graduate coursework in Human Biochemistry at Fairleigh Dickinson University.
Ray Chiu, M.D., Ph.D.
Information coming soon...
Dr. Goldschmidt [has entered] into a three-year consulting agreement with the Company to provide consulting services as Chief Consultant for Genetic Testing for the Company, including advice to the Company with respect to genetic testing and related technologies and matters. A native of Belgium, Dr. Goldschmidt earned his undergraduate degree in biochemistry and graduated magna cum laude in 1976 and earned his medical degree in 1980 and graduated summa cum laude from the Universite Libre de Bruxelles in Brussels, Belgium. Following a medicine and cardiology residency at the Erasme Academic Hospital in Belgium and a fellowship in molecular biology and immunology at the Medical University of South Carolina, Dr. Goldschmidt completed a five year residency training in cardiology and cell biology at Johns Hopkins University. In 1991, he joined the cardiology faculty of Johns Hopkins University where he was the Director of the Bernard Vascular Biology Laboratory, Co-Director of the Thrombosis Center and Co-Director of the Henry Ciccarone Center for the Prevention of Heart Disease. In 1996 he received a faculty appointment in the Department of Pathology at the Johns Hopkins University. In 1997, Dr. Goldschmidt joined The Ohio State University as a Professor of Medicine and was named the John H. and Mildred C. Lumley Chair in Medicine and the Director of the new Heart and Lung Institute after a search process that reviewed 175 leaders in the field. In 1998, Dr. Goldschmidt was named the Director of the Division of Cardiology at The Ohio State University. A landmark in Dr. Goldschmidt's career was his discovery of the first inherited thrombogenic risk factor for coronary heart disease. Dr. Goldschmidt is internationally recognized for his research in the molecular mechanisms of cardiovascular disease. He has received numerous honors, including the Established Investigator Award from the American Heart Association and is a Fellow of the American College of Cardiology. As a result of his reputation within the medical community, Dr. Goldschmidt has been selected as an expert clinician and scientist for many organizations and is a reviewer for several top medical journals including the New England Journal of Medicine, the Annals of Internal Medicine, and Circulation. He has authored or co-authored over 80 articles in all top peer-reviewed journals including Science, Cell, the New England Journal of Medicine, the Lancet and the Journal of Clinical Investigation. Dr. Goldschmidt has also been awarded several grants from the NIH, Scleroderma Research Foundation and the American Heart Association for his research in cardiovascular disease and molecular genetics. Dr. Goldschmidt is a member of and serves on many committees for the American Association for the Advancement of Science, the American Heart Association, the American Society of Clinical Investigation, the American College of Cardiology, and the American Medical Association.
James L. Greene
Mr. Greene came to BIOHEART, Inc. with combined experience of 14 years in the medical device industry serving in various positions of responsibilty starting as a clinical laboratory sales person for Abbott Diagnostics in 1986, specializing in diagnostic assay sales to blood banks and clinical and reference laboratories. He was ranked number 5 out of 266 sales reps nationwide and was quickly promoted to Capital Equipment Sales manager in the Northeast managing the sales and training activities of 8 sales people. His region ranked number one out of eight sales regions within the division.
He then took a start-up opportunity in Florida with CR Bard Radiology establishing their Interventional Radiology products through-out the state. He then was recruited by Advanced Cardiovascular Systems where he served in the roles of sales person, Product Manager of Rapid Exchange PTCA balloons. He had the pleasure to launch the most successful PTCA balloon in the US claiming over 35% of the market with the RX Elipse catheter. He was promoted to Western Regional Sales Manager and built the combined Guidant Merger of ACS and Devices for Vascular Intervention (DVI) in the Western half of the US.
He took another start-up position as German Country Manager for Perclose, Inc. and was quickly promoted to Director International Sales and Marketing, Europe. Perclose became the market leader in Percutaneous Vascular Surgery for arterial closure post-intervention.
After that he served in the Position of Director of Peripheral Sales for Arterial Vascular Engineering, hired by Robert Lashinski, and moved to Europe. He continued with a larger scope during and after the buy-out of AVE, Inc. by Medtronic as Director Peripheral Sales, Europe, Middle East, Africa and was primarily responsible for merging the three sales forces of Talent, AneuRx, and Ave, inc into Medtronic's first Peripheral Technologies division. We attained $30,000,000 in sales and the undisputed market leadership position in Endovascular Treatment of AAA Aneurysms.
Guylaine Senechal, M.S.
Ms Senechal joined Bioheart as Senior Research Associate. She is a graduate of Laval University in Quebec City, Canada, with a Baccalaureate in Microbiology and a Master's Degree in Experimental Medicine/Cardiology. Her graduate studies involved the characterization of cytoskeletal alterations following myocardial infarction. Prior to joining the company, Ms Senechal was Sr Research Associate at Osiris Therapeutics, Inc, in Baltimore where she was working on cardiac muscle regeneration using Mesenchymal Stem Cells. Ms Senechal has extensive experience in small animal cardiovascular surgery, cell biology, tissue culture, microscopy and histology. She is currently working in our biomedical testing laboratory in the Cardiovascular Engineering Center of Florida International University.
Syde A. Taheri, M.D.
Information coming soon...
Stuart Williams, M.D.
Stuart K. Williams, Ph.D., Professor of Biomedical Engineering, Surgery, Physiology, and Material Science Engineering, University of Arizona Health Sciences Center. Ph.D. Cell Biology-Physiology, U of Deleware, Post-Doc. Yale University School of Medicine. Dr. Williams is one the premier scientists in the world regarding tissue engineering. He is President of the International Society for Applied Cardiovascular Biology. He has published over 100 papers in his career related to cardiovascular biology.
Hany Hussein, Ph.D., P.E.
Dr. Hussein serves as a consultant to Bioheart Microimplants, Inc. in connection with research and development of technologies for angiogenesis and myogenesis. Dr. Hussein's services are provided from time to time upon request of the Company for an agreed per diem compensation. Dr. Hussein is a graduate of the University of Texas at Austin with a Master of Science in Biomedical Engineering degree and the Louisiana State University where he received his Doctorate of Philosophy in Mechanical Engineering. He went on to work as a research assistant at the University of Texas at Austin in the Biomedical Engineering Program investigating the structure of blood clots under a scanning electron microscope and employing a hydrodynamic test system for monitoring the viscoelastic properties of blood during coagulation. He held senior research and development positions at Abbott Laboratories and Becton-Dickinson & Company. Later, he served as the Executive Vice President of Scientific Affairs for Trimedyne, Inc. where he provided technical and business leadership towards the development of new fiberoptic devices and laser systems for medical use. He pioneered the product development for laser angioplasty, angioscopy, and laser treatment of benign prostatic hyperplasia. He is now the founder and President of Energy Life Systems Corporation, which develops medical products that provide less invasive solutions to certain medical problems. He has developed novel technologies for ablation of cardiac arrhythmias, myocardial viability monitoring, angiogenesis, and treatment of Benign Prostatic Hyperplasis. He has also obtained three research grants from the National Heart, Lung, and Blood Institute under the Small Business Innovation Research (SBIR) Program. He holds multiple United States Patents and has been published extensively. He has served as an expert witness for Medtronic, Inc., Boston Scientific Corp., and C.R. Bard, Inc.
Cardiovascular Healthcare Service based on Genotyping
|Bioheart, Inc. | |
Telephone: | Fax: | email: